PGR and breast cancer: GEP has been extensively used to classify BC into subtypes, identifying transcriptional signatures for estrogen receptor+ (ER+, luminal), human epidermal growth factor receptor 2+ (HER2+) ERBB2-amplified, and ER−, progesterone receptor− (PR−) and HER2− (basal) BC [21].